Table 1.

Baseline characteristics and mean GH dose during two-year treatment period for total and pre-pubertal patient population by indication

	Children with IGHD		Children born SGA		Children with ISS		Children with MPHD
	Total	Pre-pubertal	Total	Pre-pubertal	Total	Pre-pubertal	Total	Pre-pubertal
Total N (pre-pubertal % of total indication)	3,298	1,120 (34%)	678	434 (64%)	334	76 (23%)	272	165 (61%)
Male gender, N (%)	2,444 (74%)	778 (70%)	396 (58%)	274 (63%)	240 (72%)	59 (78%)	171 (63%)	106 (64%)
Mean chronological age ± SD (years)	10.2 ± 3.6	6.5 ± 2.8	7.9 ± 3.2	6.1 ± 2.1	10.9 ± 2.9	7.1 ± 2.3	7.9 ± 4.9	4.8 ± 3.5
Mean height SDS ± SD	−2.3 ± 1.0	−2.7 ± 1.0	−3.1 ± 0.9	−3.3 ± 0.9	−2.3 ± 0.8	−2.6 ± 0.9	−2.0 ± 1.5	−2.3 ± 1.6
Mean bone age delay from chronological age ± SD (years) [N]	−1.8 ± 1.4 [2,419]	−1.9 ± 1.3 [703]	−1.6 ± 1.4 [430]	−1.6 ± 1.2 [266]	−1.7 ± 1.5 [294]	−1.9 ± 1.4 [65]	−1.7 ± 1.8 [137]	−1.3 ± 1.7 [63]
Mean IGF-I SDS ± SD [N]	−1.8 ± 1.7 [2,784]	−1.4 ± 1.4 [890]	−0.7 ± 1.6 [434]	−0.5 ± 1.4 [276]	−1.6 ± 1.7 [308]	−1.2 ± 1.4 [66]	−1.9 ± 2.2 [222]	−1.4 ± 1.9 [133]
Mean GH dose during two-year treatment period ± SD (mg/kg/day) [N]	0.042 ± 0.013 [3,272]	0.038 ± 0.011 [1,110]	0.042 ± 0.013 [678]	0.041 ± 0.013 [434]	0.049 ± 0.012 [334]	0.046 ± 0.011 [76]	0.036 ± 0.013 [268]	0.035 ± 0.011 [163]